Eriko Murakami
Overview
Explore the profile of Eriko Murakami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Washioka A, Akamatsu H, Sugimoto T, Kitahara D, Kaki T, Murakami E, et al.
Transl Lung Cancer Res
. 2024 Dec;
13(11):3252-3255.
PMID: 39669996
Background: Lung mucinous adenocarcinoma has various genetic alterations, but there are no reported cases with exon 14 skipping mutations. Multiplex genetic testing is commonly assessed in non-small cell lung cancer...
2.
Takakura T, Akamatsu H, Washioka A, Murakami E, Shibaki R, Shimizu T, et al.
Respirol Case Rep
. 2024 Sep;
12(9):e01401.
PMID: 39220096
Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge. We report the...
3.
Murakami E, Akamatsu H, Teraoka S, Takakura T, Takase E, Tanaka M, et al.
Cancer Med
. 2024 Mar;
13(4):e6839.
PMID: 38457231
Background: Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)-based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires...
4.
Takase E, Akamatsu H, Teraoka S, Nakaguchi K, Tanaka M, Kaki T, et al.
J Pain Symptom Manage
. 2023 Nov;
67(3):204-211.e1.
PMID: 37992848
Context: The efficacy and tolerability of high-flow nasal cannula (HFNC) for relieving dyspnea in advanced cancer patients with limited prognosis requires elucidation. Objectives: The primary aim of this trial was...
5.
Harutani Y, Ozawa Y, Murakami E, Sato K, Oyanagi J, Akamatsu H, et al.
Cancer Immunol Immunother
. 2022 Jan;
71(9):2109-2116.
PMID: 35037070
While PD-1/L1 inhibitors are characterized by durable tumor control, they also prolong survival without prolongation of progression-free survival (PFS) in part of patients. However, little is known about the factors...
6.
Akamatsu H, Ozawa Y, Oyanagi J, Fujimoto D, Hata A, Katakami N, et al.
Anticancer Res
. 2021 Jan;
41(2):911-917.
PMID: 33517297
Background/aim: To explore the safety of osimertinib plus ramucirumab in patients with EGFR-mutated lung adenocarcinoma. Patients And Methods: Six advanced lung adenocarcinoma patients with EGFR mutation were treated with osimertinib...
7.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, et al.
Cancer Sci
. 2020 Oct;
112(1):72-80.
PMID: 33084148
CD24, a heavily glycosylated glycosylphosphatidylinositol-anchored surface protein, inhibits phagocytosis as potently as CD47. The relationship between such anti-phagocytic factors and the immune response with immune-checkpoint inhibitors (ICI) remains unexplored. We...
8.
Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, et al.
Oncologist
. 2020 Apr;
25(4):e679-e683.
PMID: 32297443
Background: Although predictive value of immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) have been suggested by several studies, their assessments were insufficient because patients were categorized only...
9.
Murakami E, Akamatsu H, Shimokawa T, Wada K, Yamamoto N
BMJ Open
. 2019 Dec;
9(12):e029057.
PMID: 31831529
Introduction: Cisplatin (CDDP) is a key drug for various thoracic malignancies. To avoid renal toxicity of CDDP, mannitol is routinely used, but it sometimes causes phlebitis which damages patients' quality...
10.
Sakai Y, Murakami E, Kato H, Ohyama K, Esaka Y, Yamamoto T, et al.
Biol Pharm Bull
. 2019 May;
42(5):751-757.
PMID: 31061317
It is important to evaluate the amount of daptomycin (DAP) distributed to skeletal muscles to elucidate the mechanisms related to penetration and side effects, such as myopathies. However, no attempt...